explore -WSS

explore

author：fashion 2025-10-02 07:25:04 - browse：31151

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： WHO recommends second malaria vaccine

WSS

6 solutions to address cancer drug shortages and others

Investment in vaccine development is lagging, report finds

WHO recommends second malaria vaccine

Wegovy leads to weight loss. Can it treat depression, too?

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Reconstructing family trees of blood cells may help predict disease

Wikipedia

explore

hotspot

Activists slam private health insurers over coverage restrictions

The biotech scorecard for Q4: 16 stock

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Hepatitis C has a cure — but many Americans still lack access to it

Medicare Advantage insurers face 0.2% cut to 2025 payments

Medical records are filled with copy

Study points to new risk in gene therapy death of Terry Horgan

Activists slam private health insurers over coverage restrictions

Humana’s losses in Medicare Advantage tank its stock

hotspot

Merck CEO won’t testify in Senate, citing no expertise in drug prices

New clues to why women have higher risk of autoimmune disorders

WHO recommends second malaria vaccine

CRISPR base editing slashes cholesterol levels in monkeys

Vertex non

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

leisure time

focus

explore

focus